5-Oxa-11-deoxy phenyl- and phenoxy-substituted prostalandin E1 analogs
CROSS REFERENCE TO RELATED APPLICATIONS 
     This application is a divisional of my co-pending application Ser. No. 361,990 filed May 21, 1973 now issued as U.S. Pat. No. 3,864,387. 
    
    
     BACKGROUND OF THE INVENTION 
     This invention relates to novel compositions of matter, to novel methods for producing those, and to novel chemical intermediates useful in those processes. Particularly, this invention relates to certain novel analogs of prostaglandins E 1 , F 1 .sub.α, F 1 .sub.β, A 1 , and B 1  in which the C-5 methylene (--CH 2 ) in the prostanoic acid structure is replaced by oxygen (--O--). 
     The essential material for this application, including the background of the invention, the disclosure of the invention, and the description of the preferred embodiments, including Preparations and Examples, is incorporated by reference from U.S. Pat. No. 3,864,387, columns 1- 89 inclusive, under the provisions of M.P.E.P. 608.01(p). 
     SUMMARY OF THE INVENTION 
     It is a purpose of this invention to provide novel 5-oxa prostagalandin E, F, A, and B analogs. It is a further purpose to provide novel 5-oxa prostaglandin analogs with a variety of substituents and degrees of saturation in the side chains. It is a further purpose to provide 5-oxa prostaglandin analogs having the 11-deoxy ring-structure in which the 11-hydroxy is replaced by hydrogen. It is a further purpose to provide esters, lower alkanoates, and pharmacologically acceptable salts of said analogs. It is a further purpose to provide novel processes for preparing said analogs and esters. It is still a further purpose to provide novel intermediates useful in said processes. 
     The novel prostaglandin analogs of this invention each have an oxygen (--O--) in place of the methylene (--CH 2  --) moiety at the 5-position of the prostanoic acid formula. They are represented by the generic formula ##EQU1## wherein D is one of the six carbocyclic moieties: ##SPC1## 
     Wherein ˜ indicates alpha or beta attachment of hydroxyl to the cyclopentane ring; wherein E is --CH 2  CH 2  -- or ##EQU2## wherein Q 1  is ##EQU3## wherein R 6  and R 7  are hydrogen or alkyl of one to 4 carbon atoms, inclusive, being the same or different; wherein R 1  is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive; wherein R 3  is hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro; wherein R 2  is hydrogen or fluoro, with the proviso that R 2  is fluoro only when R 3  is hydrogen or fluoro; wherein R 4  and R 5  are hydrogen or alkyl of one to 4 carbon atoms, inclusive, being the same or different with the proviso that no more than one of R 3 , R 4 , and R 5  is alkyl; and wherein R 14  is ##EQU4## with the proviso that R 14  is ##EQU5## only when E is ##EQU6## wherein C g  H 2g  is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between -CR 8  R 9  - and terminal methyl; wherein R 8  and R 9  are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that R 9  is fluoro only when R 8  is hydrogen or fluoro; wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR 10 , wherein R 10  is hydrogen or alkyl of one to 4 carbon atoms, inclusive, and s is zero, one, 2, or 3, with the proviso that not more than two T&#39;s are other than alkyl; and wherein Z represents an oxa atom (--O--) or C j  H 2j , wherein C j  H 2j  is a valence bond or alkylene of one to 9 carbon atoms, inclusive, substituted with zero, one, or 2 fluoro, with one to 6 carbon atoms, inclusive, between --CR 8  R 9  -- and the ring. 
     The presently described acids and esters of the 5-oxa prostaglandin analogs include compounds of the following formulas which are intended to represent the same optically form as of the naturally occurring prostaglandins. There are also included the racemic compounds represented by each respective formula and the mirror image thereof. There are also included the alkanoates of two to 8 carbon atoms, inclusive and also the pharmacologically acceptable salts thereof when R 1  is hydrogen. ##EQU7##